menu
    • menu
    [{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"IMSA101","moa":"STING","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneSensor Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"ImmuneSensor Therapeutics \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneSensor Therapeutics \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IMSB301","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ImmuneSensor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneSensor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IMSB301","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ImmuneSensor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneSensor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IMSB301","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ImmuneSensor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneSensor Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by ImmuneSensor Therapeutics

    Menu

    ImmuneSensor Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ImmuneSensor Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            ImmuneSensor Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMSB301

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ImmuneSensor Orphan and Pediatric Designations for IMSB301 in Aicardi Goutières Syndrome

                            Details : IMSB301 is a novel, orally available small molecule cGAS inhibitor drug candidate, that is being developed for the treatment of Aicardi Goutières Syndrome.

                            Brand Name : IMSB301

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 20, 2024

                            Lead Product(s) : IMSB301

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ImmuneSensor Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            ImmuneSensor Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMSB301

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ImmuneSensor Starts Phase 1 Trial for Lead cGAS Inhibitor IMSB301

                            Details : IMSB301 is company's lead oral cGAS inhibitor drug candidate, which is currently being evaluated for the treatment of type 1 interferonopathy and autoimmune diseases.

                            Brand Name : IMSB301

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 08, 2024

                            Lead Product(s) : IMSB301

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ImmuneSensor Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            ImmuneSensor Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMSB301

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ImmuneSensor Gets Clearance in Australia for Phase 1 Trial of cGAS Inhibitor IMSB301

                            Details : IMSB301 is a novel, orally available small molecule cGAS inhibitor drug candidate, that is being developed for the treatment of inflammatory and autoimmune diseases.

                            Brand Name : IMSB301

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 19, 2024

                            Lead Product(s) : IMSB301

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ImmuneSensor Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            ImmuneSensor Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMSA101,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Cancer Prevention and Research Institute of Texas

                            Deal Size : $16.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            ImmuneSensor Awarded $16 Million Grant from the Cancer Prevention and Research Institute of Texas (CPRIT)

                            Details : IMSA101 is a small molecule agonist of the stimulator of interferon gene protein and is currently in development for solid tumors. The agent has demonstrated tumor growth inhibition as a single agent and in combination with immune checkpoint inhibitors i...

                            Brand Name : IMSA101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 20, 2022

                            Lead Product(s) : IMSA101,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Cancer Prevention and Research Institute of Texas

                            Deal Size : $16.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth